Study on intestinal microflora and Metabonomics of Nervonic acid interfering with the progression of Alzheimer's disease by regulating intestinal flora

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000041229

Enrollment

Unknown

Registered

2020-12-22

Start date

2021-02-01

Completion date

Unknown

Last updated

2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

Group 1:N/A

Group 2:Add nervonic acid diet

Group 3:N/A

Group 4:Add nervonic acid diet

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis of the selected AD patients met the diagnostic criteria of NINCDS-ADRDA established by the national stroke Institute of neurologic disorders (NINCDS) and Alzheimer's disease and Related Diseases Association (ADRDA). 2. The patients with AD were tested with mini mental state examination (MMSE). 3. Patients with cognitive impairment were classified by MMSE < 24.

Exclusion criteria

Exclusion criteria: 1. Patients with dementia caused by other causes have been identified; 2. Patients with severe heart disease, liver and kidney dysfunction, cerebrovascular accident, malignant tumor, psychosis, brain trauma, drug alcoholism and taking drugs that may affect cognitive function; 2. Patients who do not cooperate with the examination.

Design outcomes

Primary

Measure	Time frame
mini-mental state examination;Montreal Cognitive Assessment;	—

Countries

China

Contacts

Public ContactXianyang Chen

Bao Feng Biotech (Beijing) Co., Ltd

cxyibcas@163.com+86 13681398052

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026